News Related to Annarac

Related coverage linked through entity extraction aliases.

Moleculin says MIRACLE trial nears first unblinding with blinded CRc above 40%

May 13, 2026

Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.

Moleculin Receives Japanese Patent Allowance for Annamycin Preparation Methods

Feb 17, 2026

Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.